AR039625A1 - Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona - Google Patents
Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-onaInfo
- Publication number
- AR039625A1 AR039625A1 ARP030101248A ARP030101248A AR039625A1 AR 039625 A1 AR039625 A1 AR 039625A1 AR P030101248 A ARP030101248 A AR P030101248A AR P030101248 A ARP030101248 A AR P030101248A AR 039625 A1 AR039625 A1 AR 039625A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- triazol
- bis
- phenyl
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
- 102100024304 Protachykinin-1 Human genes 0.000 abstract 1
- 101800003906 Substance P Proteins 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 abstract 1
- 229940125898 compound 5 Drugs 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La presente invención se refiere a un novedoso proceso para la preparación del compuesto 5-[[2(R)-[1(R)-[3,5-bis(trifluormetil)fenil]etoxi]-3(s)-(4-fluorfenil)-4-morfolinil]metil]-1,2-dihidro-3H-1,2,4-triazol-3-ona. Este compuesto es útil como antagonista del receptor de la sustancia P (neuroquina-1). En particular, el compuesto es útil por ejemplo en el tratamiento de trastornos psiquiátricos, enfermedades inflamatorias y emesis. Reivindicación 1: un proceso para preparar un compuesto de la fórmula (1), que comprende: ciclizar un compuesto de la fórmula (4), a una temperatura de 140-150°C a efectos de producir el compuesto de la fórmula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37373402P | 2002-04-18 | 2002-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039625A1 true AR039625A1 (es) | 2005-03-02 |
Family
ID=29251070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101248A AR039625A1 (es) | 2002-04-18 | 2003-04-09 | Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7847095B2 (es) |
| EP (1) | EP1499611B1 (es) |
| JP (1) | JP4271586B2 (es) |
| KR (1) | KR100982901B1 (es) |
| CN (1) | CN1293077C (es) |
| AR (1) | AR039625A1 (es) |
| AU (1) | AU2003228578B2 (es) |
| BR (1) | BR0309277A (es) |
| CA (1) | CA2482466C (es) |
| EG (1) | EG24127A (es) |
| HR (1) | HRP20040974A2 (es) |
| IL (1) | IL164586A (es) |
| MX (1) | MXPA04010182A (es) |
| NO (1) | NO330362B1 (es) |
| NZ (1) | NZ535883A (es) |
| PL (1) | PL217076B1 (es) |
| RU (1) | RU2326879C2 (es) |
| TW (1) | TWI341313B (es) |
| UA (1) | UA84399C2 (es) |
| WO (1) | WO2003089429A1 (es) |
| ZA (1) | ZA200408193B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400850D0 (sv) * | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| EP2266980A1 (en) | 2005-10-05 | 2010-12-29 | Ranbaxy Laboratories Limited | Polymorphic form of aprepitant intermediate |
| WO2007044829A2 (en) * | 2005-10-06 | 2007-04-19 | Dr. Reddy's Laboratories Ltd. | Preparation of aprepitant |
| US9227958B2 (en) | 2006-02-03 | 2016-01-05 | Glenmark Pharmaceuticals Limited | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof |
| US20090149462A1 (en) * | 2006-08-28 | 2009-06-11 | Hetero Drugs Limited | Process for purification of aprepitant |
| US8940890B2 (en) | 2010-05-24 | 2015-01-27 | Chengdu Di'ao Pharmaceutical Group Co., Ltd. | Preparation method of 5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl) phenyl]ethoxy]-3(S)-4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one |
| HUP1000325A2 (en) * | 2010-06-18 | 2012-01-30 | Druggability Technologies Ip Holdco Jersey Ltd | Nanostructured aprepitant compositions and process for their preparation |
| WO2012146692A1 (en) | 2011-04-29 | 2012-11-01 | Sandoz Ag | Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant |
| CN103030668B (zh) * | 2011-10-09 | 2016-06-15 | 江苏豪森药业集团有限公司 | 一种制备福沙匹坦二甲葡胺的方法 |
| PT2817305T (pt) * | 2012-02-23 | 2016-11-02 | Piramal Entpr Ltd | Um processo melhorado para a preparação de aprepitant |
| CZ304770B6 (cs) * | 2012-03-13 | 2014-10-08 | Zentiva, K.S. | Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II |
| ITMI20130273A1 (it) * | 2013-02-26 | 2014-08-27 | Olon Spa | Procedimento per la preparazione di aprepitant |
| CN103288813A (zh) * | 2013-06-04 | 2013-09-11 | 四川百利药业有限责任公司 | 一种阿瑞匹坦的制备方法 |
| CN107954998B (zh) * | 2016-10-14 | 2022-08-12 | 江苏豪森药业集团有限公司 | 福沙匹坦中间体的制备方法 |
| CN106967057A (zh) * | 2017-06-01 | 2017-07-21 | 四川制药制剂有限公司 | 一种阿瑞匹坦高效制备工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5637699A (en) | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| GB9513972D0 (en) * | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
| ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| GB9813025D0 (en) | 1998-06-16 | 1998-08-12 | Merck Sharp & Dohme | Chemical synthesis |
-
2003
- 2003-04-09 AR ARP030101248A patent/AR039625A1/es not_active Application Discontinuation
- 2003-04-10 TW TW092108229A patent/TWI341313B/zh not_active IP Right Cessation
- 2003-04-17 UA UA20041109407A patent/UA84399C2/ru unknown
- 2003-04-17 PL PL373348A patent/PL217076B1/pl unknown
- 2003-04-17 US US10/511,691 patent/US7847095B2/en active Active
- 2003-04-17 JP JP2003586150A patent/JP4271586B2/ja not_active Expired - Fee Related
- 2003-04-17 CA CA2482466A patent/CA2482466C/en not_active Expired - Fee Related
- 2003-04-17 CN CNB038084465A patent/CN1293077C/zh not_active Expired - Fee Related
- 2003-04-17 EP EP03726338.1A patent/EP1499611B1/en not_active Expired - Lifetime
- 2003-04-17 RU RU2004133678/04A patent/RU2326879C2/ru not_active IP Right Cessation
- 2003-04-17 NZ NZ535883A patent/NZ535883A/en not_active IP Right Cessation
- 2003-04-17 AU AU2003228578A patent/AU2003228578B2/en not_active Ceased
- 2003-04-17 WO PCT/US2003/011956 patent/WO2003089429A1/en active Application Filing
- 2003-04-17 MX MXPA04010182A patent/MXPA04010182A/es active IP Right Grant
- 2003-04-17 BR BR0309277-1A patent/BR0309277A/pt not_active IP Right Cessation
- 2003-04-17 KR KR1020047016622A patent/KR100982901B1/ko not_active IP Right Cessation
- 2003-04-19 EG EG2003040353A patent/EG24127A/xx active
-
2004
- 2004-10-11 ZA ZA200408193A patent/ZA200408193B/en unknown
- 2004-10-14 IL IL164586A patent/IL164586A/en not_active IP Right Cessation
- 2004-10-15 HR HR20040974A patent/HRP20040974A2/hr not_active Application Discontinuation
- 2004-11-17 NO NO20045001A patent/NO330362B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2482466A1 (en) | 2003-10-30 |
| EG24127A (en) | 2008-07-08 |
| RU2004133678A (ru) | 2005-05-27 |
| AU2003228578A1 (en) | 2003-11-03 |
| EP1499611A4 (en) | 2006-05-03 |
| KR100982901B1 (ko) | 2010-09-20 |
| PL217076B1 (pl) | 2014-06-30 |
| KR20050007299A (ko) | 2005-01-17 |
| HRP20040974A2 (en) | 2005-06-30 |
| JP4271586B2 (ja) | 2009-06-03 |
| IL164586A (en) | 2010-11-30 |
| RU2326879C2 (ru) | 2008-06-20 |
| NZ535883A (en) | 2007-12-21 |
| CA2482466C (en) | 2012-11-20 |
| BR0309277A (pt) | 2005-02-22 |
| ZA200408193B (en) | 2006-06-28 |
| JP2005529881A (ja) | 2005-10-06 |
| PL373348A1 (en) | 2005-08-22 |
| EP1499611B1 (en) | 2015-02-11 |
| TWI341313B (en) | 2011-05-01 |
| CN1646525A (zh) | 2005-07-27 |
| US20050215786A1 (en) | 2005-09-29 |
| AU2003228578B2 (en) | 2009-07-30 |
| NO20045001L (no) | 2004-11-17 |
| MXPA04010182A (es) | 2005-02-03 |
| WO2003089429A1 (en) | 2003-10-30 |
| CN1293077C (zh) | 2007-01-03 |
| US7847095B2 (en) | 2010-12-07 |
| EP1499611A1 (en) | 2005-01-26 |
| TW200400189A (en) | 2004-01-01 |
| UA84399C2 (en) | 2008-10-27 |
| IL164586A0 (en) | 2005-12-18 |
| NO330362B1 (no) | 2011-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039625A1 (es) | Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona | |
| BR0214786A (pt) | Composições nanoparticulada e farmacêutica, e, métodos para a antagonização do efeito de substância p em seu sìtio receptor ou para o bloqueio de receptores de neurocinina-1 em um paciente, para o tratamento de depressão em um paciente, para o tratamento ou a prevenção de ansiedade em um paciente e para o tratamento ou a prevenção de êmese em um paciente | |
| JP2009504791A5 (es) | ||
| PE20121440A1 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos | |
| US20060154899A1 (en) | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma | |
| MA28290A1 (fr) | Procede de preparation | |
| JP2005525324A5 (es) | ||
| RU2010138840A (ru) | Производные оксазолидинона | |
| RU2008116828A (ru) | Комбинированный метод терапии замещенными оксазолидинонами для профилактики и лечения нарушений церебрального местного кровообращения | |
| PE20081378A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
| WO2014114532A1 (en) | Fluoro-[1,3]oxazines as bace1 inhibitors | |
| RU2008109908A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| WO2006123257A3 (en) | Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors | |
| RU2003107016A (ru) | Замещенные пиразолы | |
| PE20030702A1 (es) | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares | |
| PT1910348T (pt) | Compostos de benzotiazol e azabenzotiazol úteis como inibidores de quinases | |
| TW200631959A (en) | Process for {3-[2(R)-[(1R)-1-[3, 5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-4, 5-dihydro-[1, 2, 4]-triazol-1-yl}phosphonic acid | |
| AU2010303545B2 (en) | 2H-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators | |
| KR20010021645A (ko) | 티아디아졸릴 및 옥사디아졸릴 페닐 옥사졸리디논 항균제 | |
| WO2004063190A1 (en) | Fused heterocyclic derivates as ppar modulators | |
| PE20070355A1 (es) | Antagonistas de cgrp seleccionados y procedimientos para su preparacion | |
| RU2010129113A (ru) | Производные 5-аминоциклилметилоксазолидин-2-она | |
| PE20071168A1 (es) | Compuestos derivados de 5,6-difenilfuro[2,3-d]pirimidina como activadores no prostanoides del receptor ip | |
| RU2011118497A (ru) | Оксазолидиниловые антибиотики | |
| RU2002102248A (ru) | Дигидробензодиазепины и их применение при лечении дислипидаемии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |